Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases

Background: Limited pharmacotherapy and the failure of conventional treatments in complex pathologies in children lead to increased off-label use of rituximab. We aimed to characterize the time course of CD19+ B lymphocytes (CD19+) under treatment with intravenous rituximab in children with neurolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Riva, Natalia, Brstilo, Lucas, Sancho-Araiz, Aymara, Molina, Manuel, Savransky, Andrea, Roffé, Georgina, Sanz, Marianela, Tenembaum, Silvia, Katsicas, Maria M., Trocóniz, Iñaki F., Schaiquevich, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674351/
https://www.ncbi.nlm.nih.gov/pubmed/38004515
http://dx.doi.org/10.3390/pharmaceutics15112534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674351/
https://www.ncbi.nlm.nih.gov/pubmed/38004515
http://dx.doi.org/10.3390/pharmaceutics15112534

Ejemplares similares